<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="ro">
	<id>https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=BioCardia%2C_Inc.</id>
	<title>BioCardia, Inc. - Revizia istoricului</title>
	<link rel="self" type="application/atom+xml" href="https://wiki.tradeville.ro/index.php?action=history&amp;feed=atom&amp;title=BioCardia%2C_Inc."/>
	<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=BioCardia,_Inc.&amp;action=history"/>
	<updated>2026-04-07T08:15:22Z</updated>
	<subtitle>Istoricul versiunilor pentru această pagină din wiki</subtitle>
	<generator>MediaWiki 1.39.2</generator>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=BioCardia,_Inc.&amp;diff=447499&amp;oldid=prev</id>
		<title>127.0.0.1: The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=BioCardia,_Inc.&amp;diff=447499&amp;oldid=prev"/>
		<updated>2024-09-29T12:10:55Z</updated>

		<summary type="html">&lt;p&gt;The LinkTitles extension automatically added links to existing pages (https://github.com/bovender/LinkTitles).&lt;/p&gt;
&lt;table style=&quot;background-color: #fff; color: #202122;&quot; data-mw=&quot;interface&quot;&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;col class=&quot;diff-marker&quot; /&gt;
				&lt;col class=&quot;diff-content&quot; /&gt;
				&lt;tr class=&quot;diff-title&quot; lang=&quot;ro&quot;&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;← Versiunea anterioară&lt;/td&gt;
				&lt;td colspan=&quot;2&quot; style=&quot;background-color: #fff; color: #202122; text-align: center;&quot;&gt;Versiunea de la data 29 septembrie 2024 15:10&lt;/td&gt;
				&lt;/tr&gt;&lt;tr&gt;&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot; id=&quot;mw-diff-left-l2&quot;&gt;Linia 2:&lt;/td&gt;
&lt;td colspan=&quot;2&quot; class=&quot;diff-lineno&quot;&gt;Linia 2:&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Descriere companie==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Descriere companie==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;−&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #ffe49c; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. It is an autologous cell therapy being advanced for two indications in pivotal clinical trials. The CardiAMP Heart Failure Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for heart attack (BCDA-01) indication. The CardiAMP Chronic Myocardial Ischemia Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for chronic myocardial ischemia (BCDA-02) indication.&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot; data-marker=&quot;+&quot;&gt;&lt;/td&gt;&lt;td style=&quot;color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #a3d3ff; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening &lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;[[&lt;/ins&gt;test&lt;ins style=&quot;font-weight: bold; text-decoration: none;&quot;&gt;]]&lt;/ins&gt;, a point of care cell processing platform, and a biotherapeutic delivery system. It is an autologous cell therapy being advanced for two indications in pivotal clinical trials. The CardiAMP Heart Failure Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for heart attack (BCDA-01) indication. The CardiAMP Chronic Myocardial Ischemia Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for chronic myocardial ischemia (BCDA-02) indication.&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;br/&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Grafic actiuni companie==&lt;/div&gt;&lt;/td&gt;&lt;td class=&quot;diff-marker&quot;&gt;&lt;/td&gt;&lt;td style=&quot;background-color: #f8f9fa; color: #202122; font-size: 88%; border-style: solid; border-width: 1px 1px 1px 4px; border-radius: 0.33em; border-color: #eaecf0; vertical-align: top; white-space: pre-wrap;&quot;&gt;&lt;div&gt;==Grafic actiuni companie==&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;

&lt;!-- diff cache key tradeville_wiki:diff::1.12:old-408869:rev-447499 --&gt;
&lt;/table&gt;</summary>
		<author><name>127.0.0.1</name></author>
	</entry>
	<entry>
		<id>https://wiki.tradeville.ro/index.php?title=BioCardia,_Inc.&amp;diff=408869&amp;oldid=prev</id>
		<title>Admin: Pagină nouă: Pagina dedicata companiei BioCardia, Inc. listata cu simbolul US.BCDA  ==Descriere companie== BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a poin...</title>
		<link rel="alternate" type="text/html" href="https://wiki.tradeville.ro/index.php?title=BioCardia,_Inc.&amp;diff=408869&amp;oldid=prev"/>
		<updated>2024-09-18T13:41:31Z</updated>

		<summary type="html">&lt;p&gt;Pagină nouă: Pagina dedicata companiei BioCardia, Inc. listata cu simbolul US.BCDA  ==Descriere companie== BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a poin...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Pagină nouă&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Pagina dedicata companiei BioCardia, Inc. listata cu simbolul US.BCDA&lt;br /&gt;
&lt;br /&gt;
==Descriere companie==&lt;br /&gt;
BioCardia, Inc. (www.biocardia.com) is a clinical-stage regenerative medicine company. It develops novel autologous and allogeneic therapeutics for cardiovascular and pulmonary diseases. Its CardiAMP Cell Therapy System (CardiAMP) is its lead therapeutic program being advanced for two clinical indications. This cell therapy system is comprised of a cell potency screening test, a point of care cell processing platform, and a biotherapeutic delivery system. It is an autologous cell therapy being advanced for two indications in pivotal clinical trials. The CardiAMP Heart Failure Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for heart attack (BCDA-01) indication. The CardiAMP Chronic Myocardial Ischemia Trial is a pivotal Phase III trial, which is designed to provide the primary support for the safety and efficacy of the CardiAMP Cell Therapy System for chronic myocardial ischemia (BCDA-02) indication.&lt;br /&gt;
&lt;br /&gt;
==Grafic actiuni companie==&lt;br /&gt;
&amp;lt;iframe key=&amp;quot;tradeville&amp;quot; path=&amp;quot;graficSimbol/US.BCDA&amp;quot; /&amp;gt;&lt;br /&gt;
&lt;br /&gt;
==Ultimele stiri despre BioCardia, Inc. (US.BCDA)==&lt;br /&gt;
&amp;lt;dynamicpagelist&amp;gt;&lt;br /&gt;
category=US.BCDA&lt;br /&gt;
count=10&lt;br /&gt;
order=descending&lt;br /&gt;
addfirstcategorydate=false&lt;br /&gt;
&amp;lt;/dynamicpagelist&amp;gt;&lt;br /&gt;
&lt;br /&gt;
[[Categorie:US.BCDA]][[Categorie:Stiri despre companii]]&lt;/div&gt;</summary>
		<author><name>Admin</name></author>
	</entry>
</feed>